Patents Examined by David Lukton
  • Patent number: 9801924
    Abstract: The present invention relates to a therapy for vitiligo. In particular the present invention provides a pharmaceutical composition comprising an alpha melanocyte stimulating hormone (alpha-MSH) analog either alone, in combination with narrow band UVB and/or in combination with one or more corticosteroids, immunosuppressants, anti-inflammatory agents and/or photochemotherapeutic agents for the treatment or prevention of vitiligo.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: October 31, 2017
    Assignee: Clinuvel Pharmaceuticals Limited
    Inventor: Philippe Wolgen
  • Patent number: 9795678
    Abstract: A composition, in the form of an aqueous solution, including insulin in hexameric form, at least one substituted anionic compound of non-saccharide structure and at least one polyanionic compound other than the substituted anionic compound.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: October 24, 2017
    Assignee: ADOCIA
    Inventors: Olivier Soula, Richard Charvet, Bertrand Alluis
  • Patent number: 9765114
    Abstract: A novel compound of the formula (1): wherein X is a tyrosine residue or a methionine residue; Y and Z each are a single bond or the like; R1 is a hydrogen atom or the like; R2 is a hydroxy group or the like; R3 is a hydrogen atom, alkyl group, amino group or the like; R4 is a hydrogen atom, alkyl group, carboxy group or the like; m is 1 or 2; and n is an integer of 0 to 2, with the proviso that when n is 0, R3 is a hydrogen atom or an alkyl group, or a pharmaceutically acceptable salt thereof, and its use in cancer immunotherapy.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: September 19, 2017
    Assignees: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC., SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventors: Toshio Nishihara, Masashi Gotoh
  • Patent number: 9750705
    Abstract: This invention provides methods of identifying agents useful to prevent, ameliorate or treat one or more symptoms of impaired insulin sensitivity, glucose tolerance, obesity, diabetes, aging, metabolic syndrome, or other metabolic syndrome component diseases, and methods of employing the identified agents to prevent, reduce, delay or inhibit one or more symptoms of impaired insulin sensitivity, glucose tolerance, obesity, diabetes, aging, metabolic syndrome, or other metabolic syndrome component diseases.
    Type: Grant
    Filed: August 30, 2013
    Date of Patent: September 5, 2017
    Assignee: The Regents of the University of California
    Inventors: Gino Cortopassi, Alexey Tomilov
  • Patent number: 9731048
    Abstract: An isolated peptide is disclosed. The peptide comprises a titanium oxide binding amino acid sequence connected to a heterologous biologically active amino acid sequence via a beta sheet breaker linker, wherein: (i) the titanium oxide binding amino acid sequence is selected to bind coordinatively with titanium oxide; (ii) the titanium oxide binding amino acid sequence is selected to induce a beta sheet structure; and (ii) the titanium oxide binding amino acid sequence binds to titanium oxide with a higher affinity than said biologically active amino acid sequence binds to the titanium oxide under physiological conditions. Use of the peptides and titanium devices comprising same are also disclosed.
    Type: Grant
    Filed: June 3, 2013
    Date of Patent: August 15, 2017
    Assignee: Ben-Gurion University of the Negev Research and Development Authority
    Inventors: Hanna Rapaport, Anna Gittelman
  • Patent number: 9731027
    Abstract: The present invention relates to novel somatostatin-dopamine chimeric analogs and their therapeutic uses for the inhibition, prevention, and/or treatment of neoplasia, neuroendocrine tumors, Cushing's disease/syndrome, and other conditions.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: August 15, 2017
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin Dong, Yeelana Shen, Sun Hyuk Kim
  • Patent number: 9731012
    Abstract: The invention provides compositions and methods for laser actuated drug delivery. Compositions comprise serum albumin based particles conjugated with therapeutic agents which cab become bioavailable upon actuation of the particles by light, e.g. low power laser.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: August 15, 2017
    Assignee: President and Fellows of Harvard College
    Inventors: Praveen Arany, David J. Mooney
  • Patent number: 9714270
    Abstract: The invention relates to thioether monomer and dimer peptide molecules which inhibit binding of ?4?7 to the mucosal addressing cell adhesion molecule (MAdCAM) in vivo.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: July 25, 2017
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Dinesh V. Patel, Genet Zemede, Brian Troy Frederick, Larry C. Mattheakis
  • Patent number: 9707275
    Abstract: A stable aqueous insulin preparation comprising human insulin, analogs or derivatives thereof, one or more solubility enhancing agents are selected from urea, amino acids and/or surfactants optionally one or more other pharmaceutically acceptable excipient(s).
    Type: Grant
    Filed: May 24, 2013
    Date of Patent: July 18, 2017
    Assignee: WOCKHARDT LIMITED
    Inventors: Maharaj K Sahib, Jeetendra Kashinath Ambulge, Gauravkumar Ramanlal Agrawal
  • Patent number: 9694086
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: July 4, 2017
    Assignee: Celgene CAR LLC
    Inventors: Russell C. Petter, Juswinder Singh, Arthur F. Kluge, Deqiang Niu, Lixin Qiao, Shomir Ghosh
  • Patent number: 9687562
    Abstract: Polymeric conjugates of a polymeric backbone formed of a plurality of backbone units and having attached to portions of the backbone units two or more therapeutically active agents, or one or more therapeutically active agents and a NCAM targeting moiety, are disclosed. Uses of such polymeric conjugates in treating and/or monitoring cancer and/or medical conditions associated with angiogenesis are also disclosed.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: June 27, 2017
    Assignee: Ramot at Tel-Aviv University Ltd.
    Inventors: Ronit Satchi-Fainaro, Ela Markovsky, Hemda Baabur-Cohen
  • Patent number: 9683213
    Abstract: Hydrogel compositions and methods of using hydrogel compositions are disclosed. Advantageously, the hydrogel compositions offer the ability to promote cellular expansion and/or cellular differentiation of various cells.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: June 20, 2017
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: William L. Murphy, Matthew Brian Parlato, James A Molenda, Ngoc Nhi Le
  • Patent number: 9682122
    Abstract: The present invention relates to a method for the treatment of vascular dysfunction, reducing ischemic pain and/or treatment of a vascular disease comprising administering a therapeutically effective amount of Annexin A5 or a functional analog or variant thereof to a patient in need of such treatment. The vascular dysfunction, ischemic pain and/or vascular disease may be associated with impaired endothelium mediated vasodilatation, a reduced eNOS activity, and/or a reduced NO bioavailability. The patient may be suffering from a disease selected from angina pectoris, ischemic heart disease, peripheral artery disease, systolic hypertension, migraine, type 2 diabetes and erectile dysfunction.
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: June 20, 2017
    Assignee: ANNEXIN PHARMACEUTICALS AB
    Inventors: Johan Frostegård, Knut Pettersson
  • Patent number: 9676823
    Abstract: A polypeptide with a predominantly hydrophobic sequence long enough to span a membrane lipid bilayer as a transmembrane helix (TM) and comprising one or more dissociable groups inserts across a membrane spontaneously in a pH-dependant fashion placing one terminus inside cell. The polypeptide conjugated with various functional moieties delivers and accumulates them at cell membrane with low extracellular pH. The functional moiety conjugated with polypeptide terminus placed inside cell are translocated through the cell membrane in cytosol. The peptide and its variants or non-peptide analogs can be used to deliver therapeutic, prophylactic, diagnostic, imaging, gene regulation, cell regulation, or immunologic agents to or inside of cells in vitro or in vivo in tissue at low extracellular pH.
    Type: Grant
    Filed: April 22, 2014
    Date of Patent: June 13, 2017
    Assignees: Rhode Island Council on Postsecondary Education (statutory successor to Board of Governors for Higher Education, State of Rhode Island and Providence Plantations), Yale University
    Inventors: Yana K. Reshetnyak, Oleg A. Andreev, Ursula Lehnert, Donald M. Engelman
  • Patent number: 9657061
    Abstract: The present invention relates to a hydrochloride salt of a peptide consisting of the sequence of CPAVKRDVDLFLT (SEQ ID NO: 1) as well as its combinations with other peptides for immunosuppressive purposes.
    Type: Grant
    Filed: May 9, 2013
    Date of Patent: May 23, 2017
    Assignee: Circassia Limited
    Inventors: Paul Laidler, Imre Farkas
  • Patent number: 9655973
    Abstract: Disclosed are compositions and methods useful for oral delivery of targeted therapies for pulmonary diseases, fibrotic disorders and cancer. The compositions and methods are based on peptide sequences that selectively bind to and home to diseased tissue and enable targeted therapies to affect a beneficial therapeutic result. The disclosed targeting is useful for oral delivery of therapeutic and detectable agents to diseased tissue in an animal.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: May 23, 2017
    Assignee: Vascular Biosciences
    Inventor: David M. Mann
  • Patent number: 9649355
    Abstract: The present invention relates to a method for the treatment of vascular dysfunction, reducing ischemic pain and/or treatment of a vascular disease comprising administering a therapeutically effective amount of Annexin A5 or a functional analog or variant thereof to a patient in need of such treatment. The vascular dysfunction, ischemic pain and/or vascular disease may be associated with impaired endothelium mediated vasodilatation, a reduced eNOS activity, and/or a reduced NO bioavailability. The patient may be suffering from a disease selected from angina pectoris, ischemic heart disease, peripheral artery disease, systolic hypertension, migraine, type 2 diabetes and erectile dysfunction.
    Type: Grant
    Filed: July 31, 2014
    Date of Patent: May 16, 2017
    Assignee: ANNEXIN PHARMACEUTICALS AB
    Inventors: Johan Frostegård, Knut Pettersson
  • Patent number: 9650414
    Abstract: The invention provides in part, compounds according to Formula I: and uses thereof.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: May 16, 2017
    Assignee: Simon Fraser University
    Inventors: Robert N. Young, Gang Chen, Haibo Xie
  • Patent number: 9644180
    Abstract: Compositions comprising synthetic membrane-receiver complexes, methods of generating synthetic membrane-receiver complexes, and methods of treating or preventing diseases, disorders or conditions therewith.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: May 9, 2017
    Assignee: RUBIUS THERAPEUTICS, INC.
    Inventors: Avak Kahvejian, Jordi Mata-Fink, John Round, David Arthur Berry, Noubar B. Afeyan
  • Patent number: 9629893
    Abstract: The present invention relates to a proteinaceous extract derived from tortoise spleen and to a tetrapeptide FTGN, which have stimulatory activity on hematopoietic cells. In particular, this tetrapeptide enhances hemopoietic reconstruction, and bone marrow re-population, reduced as a consequence of a high dose of radiation or chemotherapy exposure. The invention further provides pharmaceutical compositions comprising as an effective ingredient the proteinaceous extract or the FTGN tetrapeptide and ex vivo and in vivo methods of treatment employing them.
    Type: Grant
    Filed: July 30, 2015
    Date of Patent: April 25, 2017
    Assignee: BMR Solutions Ltd.
    Inventor: Azim Turdiev